Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
<p>Abstract</p> <p>Background</p> <p>Escitalopram is licensed for use at doses up to 20 mg but is used clinically at higher doses. There is limited published data at higher doses and none in the treatment of Major Depressive Disorder (MDD).</p> <p>Methods<...
Main Authors: | Crawford Gordon M, Wade Alan G, Yellowlees Ann |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-03-01
|
Series: | BMC Psychiatry |
Online Access: | http://www.biomedcentral.com/1471-244X/11/42 |
Similar Items
-
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
by: DEVELOPMENT GROUP MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) MOH MALAYSIA
Published: (2011-01-01) -
Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
by: Michael Leutner, et al.
Published: (2021-02-01) -
Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
by: Jiang KD, et al.
Published: (2017-02-01) -
Unilateral galactorrhea associated with low-dose escitalopram
by: P Bangalore Ravi, et al.
Published: (2014-01-01) -
Corrigendum: Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment
by: Michael Leutner, et al.
Published: (2021-04-01)